Base de dados : MEDLINE
Pesquisa : D06.472.699.322 [Categoria DeCS]
Referências encontradas : 7838 [refinar]
Mostrando: 1 .. 10   no formato [Detalhado]

página 1 de 784 ir para página                         

  1 / 7838 MEDLINE  
              next record last record
seleciona
para imprimir
Fotocópia
[PMID]:29424977
[Au] Autor:Santibáñez-Morales A; Durán-Boullosa E; Colín-Licea EO
[Ti] Título:[Use of growth hormone for in vitro fertilization].
[Ti] Título:Indicación de hormona de crecimiento en ciclos de fertilización in vitro..
[So] Source:Ginecol Obstet Mex;84(9):567-72, 2016 Sep.
[Is] ISSN:0300-9041
[Cp] País de publicação:Mexico
[La] Idioma:spa
[Ab] Resumo:Background: Ovarian stimulation is the cornerstone in fertility treatments, it produces multifolicular development and in consequence, a greater pregnancy rate. Poor responder patients have bad outcomes in IVF, several medical approaches have been proposed in managing these patients, including Growth Hormone. Objetive: To report our results with the use of growth hormone and review published data. Material and method: Case series conducted from January 2013 to May 2015 in patients to Centro de Reproducción PROCREA, Mexico City, poor responders according to the criteria of consensus Bologna cycles in fresh stimulation protocol Flare up, application of growth hormone as adjuvant, complete cycles of stimulation (stimulation, oocyte capture, and embryo transfer pregnancy test) and complete records. For statistical analysis, averages and percentages were used. Results: 40 cases were analyzed. Age and BMI were 39.1 ± 2.1 years and 24.6 ± 2.8 kg/m2, respectively. Total gonadotrophin dose was 2128.6 ± 1078.9 UI, retrieved oocytes and fertilized eggs were 7.1 ± 4.0 y 5.4 ± 2.8 respectively. Fertilization rate was 76.3% and pregnancy rate was 59.5%. Conclusion: There is insufficient evidence for prescribing GH in all patients requiring IVF, nevertheless, in poor responder patients, there seems to be an improvement in egg quality leading to better fertilization and pregnancy rate, with no adverse effects.
[Mh] Termos MeSH primário: Fertilização In Vitro/métodos
Hormônio do Crescimento/administração & dosagem
Indução da Ovulação/métodos
[Mh] Termos MeSH secundário: Adulto
Feminino
Gonadotropinas/administração & dosagem
Seres Humanos
México
Gravidez
Taxa de Gravidez
Resultado do Tratamento
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadotropins); 9002-72-6 (Growth Hormone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180210
[St] Status:MEDLINE


  2 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
Texto completo
[PMID]:29368795
[Au] Autor:Kop PA; Mochtar MH; O'Brien PA; Van der Veen F; van Wely M
[Ad] Endereço:Obstetrics and Gynaecology, Center for Reproductive Medicine, Academic Medical Centre, Meibergdreef 9, Amsterdam, Netherlands, 1105 AZ.
[Ti] Título:Intrauterine insemination versus intracervical insemination in donor sperm treatment.
[So] Source:Cochrane Database Syst Rev;1:CD000317, 2018 01 25.
[Is] ISSN:1469-493X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:BACKGROUND: The first-line treatment in donor sperm treatment consists of inseminations that can be done by intrauterine insemination (IUI) or by intracervical insemination (ICI). OBJECTIVES: To compare the effectiveness and safety of intrauterine insemination (IUI) and intracervical insemination (ICI) in women who start donor sperm treatment. SEARCH METHODS: We searched the Cochrane Gynaecology and Fertility Group Trials Register, CENTRAL, MEDLINE, Embase, PsycINFO, CINAHL in October 2016, checked references of relevant studies, and contacted study authors and experts in the field to identify additional studies. We searched PubMed, Google Scholar, the Grey literature, and five trials registers on 15 December 2017. SELECTION CRITERIA: We included randomised controlled trials (RCTs) reporting on IUI versus ICI in natural cycles or with ovarian stimulation, and RCTs comparing different cointerventions in IUI and ICI. We included cross-over studies if pre-cross-over data were available. DATA COLLECTION AND ANALYSIS: We used standard methodological procedures recommended by Cochrane. We collected data on primary outcomes of live birth and multiple pregnancy rates, and on secondary outcomes of clinical pregnancy, miscarriage, and cancellation rates. MAIN RESULTS: We included six RCTs (708 women analysed) on ICI and IUI in donor sperm treatment. Two studies compared IUI and ICI in natural cycles, two studies compared IUI and ICI in gonadotrophin-stimulated cycles, and two studies compared timing of IUI and ICI. There was very low-quality evidence; the main limitations were risk of bias due to poor reporting of study methods, and serious imprecision.IUI versus ICI in natural cyclesThere was insufficient evidence to determine whether there was any clear difference in live birth rate between IUI and ICI in natural cycles (odds ratio (OR) 3.24, 95% confidence interval (CI) 0.12 to 87.13; 1 RCT, 26 women; very low-quality evidence). There was only one live birth in this study (in the IUI group). IUI resulted in higher clinical pregnancy rates (OR 6.18, 95% CI 1.91 to 20.03; 2 RCTs, 76 women; I² = 48%; very low-quality evidence).No multiple pregnancies or miscarriages occurred in this study.IUI versus ICI in gonadotrophin-stimulated cyclesThere was insufficient evidence to determine whether there was any clear difference in live birth rate between IUI and ICI in gonadotrophin-stimulated cycles (OR 2.55, 95% CI 0.72 to 8.96; 1 RCT, 43 women; very low-quality evidence). This suggested that if the chance of a live birth following ICI in gonadotrophin-stimulated cycles was assumed to be 30%, the chance following IUI in gonadotrophin-stimulated cycles would be between 24% and 80%. IUI may result in higher clinical pregnancy rates than ICI (OR 2.83, 95% CI 1.38 to 5.78; 2 RCTs, 131 women; I² = 0%; very low-quality evidence). IUI may be associated with higher multiple pregnancy rates than ICI (OR 2.77, 95% CI 1.00 to 7.69; 2 RCTs, 131 women; I² = 0%; very low-quality evidence). This suggested that if the risk of multiple pregnancy following ICI in gonadotrophin-stimulated cycles was assumed to be 10%, the risk following IUI would be between 10% and 46%.We found insufficient evidence to determine whether there was any clear difference between the groups in miscarriage rates in gonadotrophin-stimulated cycles (OR 1.97, 95% CI 0.43 to 9.04; 2 RCTs, overall 67 pregnancies; I² = 50%; very low-quality evidence).Timing of IUI and ICIWe found no studies that reported on live birth rates.We found a higher clinical pregnancy rate when IUI was timed one day after a rise in blood levels of luteinising hormone (LH) compared to IUI two days after a rise in blood levels of LH (OR 2.00, 95% CI 1.14 to 3.53; 1 RCT, 351 women; low-quality evidence). We found insufficient evidence to determine whether there was any clear difference in clinical pregnancy rates between ICI timed after a rise in urinary levels of LH versus a rise in basal temperature plus cervical mucus scores (OR 1.31, 95% CI 0.42 to 4.11; 1 RCT, 56 women; very low-quality evidence).Neither of these studies reported multiple pregnancy or miscarriage rates as outcomes. AUTHORS' CONCLUSIONS: There was insufficient evidence to determine whether there was a clear difference in live birth rates between IUI and ICI in natural or gonadotrophin-stimulated cycles in women who started with donor sperm treatment. There was insufficient evidence available for the effect of timing of IUI or ICI on live birth rates. Very low-quality data suggested that in gonadotrophin-stimulated cycles, ICI may be associated with a higher clinical pregnancy rate than IUI, but also with a higher risk of multiple pregnancy rate. We concluded that the current evidence was too limited to choose between IUI or ICI, in natural cycles or with ovarian stimulation, in donor sperm treatment.
[Mh] Termos MeSH primário: Inseminação Artificial Heteróloga/métodos
[Mh] Termos MeSH secundário: Temperatura Corporal
Muco do Colo Uterino
Feminino
Gonadotropinas/uso terapêutico
Seres Humanos
Nascimento Vivo/epidemiologia
Hormônio Luteinizante/sangue
Ciclo Menstrual/efeitos dos fármacos
Gravidez
Taxa de Gravidez
Gravidez Múltipla
Ensaios Clínicos Controlados Aleatórios como Assunto
[Pt] Tipo de publicação:COMPARATIVE STUDY; JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadotropins); 9002-67-9 (Luteinizing Hormone)
[Em] Mês de entrada:1803
[Cu] Atualização por classe:180301
[Lr] Data última revisão:
180301
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180126
[St] Status:MEDLINE
[do] DOI:10.1002/14651858.CD000317.pub4


  3 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29315384
[Au] Autor:Li S; Mbong EF; John DT; Terasaka T; Li D; Lawson MA
[Ad] Endereço:Department of Reproductive Medicine, University of California, San Diego, La Jolla, California.
[Ti] Título:Induction of Stress Signaling In Vitro and Suppression of Gonadotropin Secretion by Free Fatty Acids in Female Mouse Gonadotropes.
[So] Source:Endocrinology;159(2):1074-1087, 2018 02 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:An emerging body of evidence supports the concept that the pituitary is a site for integration of multiple physiological and metabolic signals that inform and modulate endocrine pathways. Multiple endocrine mediators of energy balance and adiposity are known to impinge on the neuroendocrine axis regulating reproduction. Observations in humans show that obesity is correlated with decreased gonadotropin secretion, and studies have also suggested that pituitary sensitivity to stimulation by gonadotropin-releasing hormone (GnRH) is decreased in obese individuals. Free fatty acids are a potential mediator of adiposity and energy balance, but their impact as an endocrine modulator of pituitary function has not been closely examined. We evaluated the impact of free fatty acids on a pituitary gonadotrope cell line and in primary pituitary cultures of female mice. We show that increasing physiologically relevant doses of the monounsaturated ω-9 fatty acid oleate induces cellular stress and increases production of reactive oxygen species in a mouse gonadotrope cell line. In contrast, the unsaturated ω-3 α-linolenic and ω-6 linoleic fatty acids do not have this effect. Additionally, oleate can activate immediate-early gene expression independent of GnRH stimulation but has a negative impact on GnRH induction and expression of the gonadotropin subunit gene Lhb. Further, oleate suppresses gonadotropin secretion in response to pulsatile stimulation by GnRH. These results indicate that free fatty acids can directly alter gonadotropin gene expression and secretion in response to GnRH and may provide a link between energy sensing and reproduction.
[Mh] Termos MeSH primário: Ácidos Graxos não Esterificados/farmacologia
Gonadotrofos/efeitos dos fármacos
Gonadotropinas/secreção
Estresse Fisiológico/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Células Cultivadas
Feminino
Gonadotrofos/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Transdução de Sinais/efeitos dos fármacos
[Pt] Tipo de publicação:JOURNAL ARTICLE; RESEARCH SUPPORT, N.I.H., EXTRAMURAL; RESEARCH SUPPORT, NON-U.S. GOV'T
[Nm] Nome de substância:
0 (Fatty Acids, Nonesterified); 0 (Gonadotropins)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180223
[Lr] Data última revisão:
180223
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:180110
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00638


  4 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29339528
[Au] Autor:Engels M; Gehrmann K; Falhammar H; Webb EA; Nordenström A; Sweep FC; Span PN; van Herwaarden AE; Rohayem J; Richter-Unruh A; Bouvattier C; Köhler B; Kortmann BB; Arlt W; Roeleveld N; Reisch N; Stikkelbroeck NMML; Claahsen-van der Grinten HL; dsd-LIFE group
[Ad] Endereço:Department of PediatricsAmalia Children's Hospital, Radboud University Medical Center, Nijmegen, the Netherlands.
[Ti] Título:Gonadal function in adult male patients with congenital adrenal hyperplasia.
[So] Source:Eur J Endocrinol;178(3):285-294, 2018 Mar.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:CONTEXT: Current knowledge on gonadal function in congenital adrenal hyperplasia (CAH) is mostly limited to single-center/country studies enrolling small patient numbers. Overall data indicate that gonadal function can be compromised in men with CAH. OBJECTIVE: To determine gonadal function in men with CAH within the European 'dsd-LIFE' cohort. DESIGN: Cross-sectional clinical outcome study, including retrospective data from medical records. METHODS: Fourteen academic hospitals included 121 men with CAH aged 16-68 years. Main outcome measures were serum hormone concentrations, semen parameters and imaging data of the testes. RESULTS: At the time of assessment, 14/69 patients had a serum testosterone concentration below the reference range; 7 of those were hypogonadotropic, 6 normogonadotropic and 1 hypergonadotropic. In contrast, among the patients with normal serum testosterone (55/69), 4 were hypogonadotropic, 44 normogonadotropic and 7 hypergonadotropic. The association of decreased testosterone with reduced gonadotropin concentrations (odds ratio (OR) = 12.8 (2.9-57.3)) was weaker than the association between serum androstenedione/testosterone ratio ≥1 and reduced gonadotropin concentrations (OR = 39.3 (2.1-732.4)). Evaluation of sperm quality revealed decreased sperm concentrations (15/39), motility (13/37) and abnormal morphology (4/28). Testicular adrenal rest tumor (TART)s were present in 39/80 patients, with a higher prevalence in patients with the most severe genotype (14/18) and in patients with increased current 17-hydroxyprogesterone 20/35) or androstenedione (12/18) serum concentrations. Forty-three children were fathered by 26/113 patients. CONCLUSIONS: Men with CAH have a high risk of developing hypothalamic-pituitary-gonadal disturbances and spermatogenic abnormalities. Regular assessment of endocrine gonadal function and imaging for TART development are recommended, in addition to measures for fertility protection.
[Mh] Termos MeSH primário: Hiperplasia Suprarrenal Congênita/sangue
Androstenodiona/sangue
Gonadotropinas/sangue
Hipogonadismo/sangue
Testosterona/sangue
[Mh] Termos MeSH secundário: Adolescente
Hiperplasia Suprarrenal Congênita/complicações
Hiperplasia Suprarrenal Congênita/epidemiologia
Tumor de Resto Suprarrenal/sangue
Tumor de Resto Suprarrenal/epidemiologia
Adulto
Idoso
Estudos Transversais
Europa (Continente)/epidemiologia
Seres Humanos
Hidroxiprogesteronas/sangue
Hipogonadismo/complicações
Masculino
Meia-Idade
Razão de Chances
Oligospermia/complicações
Prevalência
Análise do Sêmen
Contagem de Espermatozoides
Motilidade Espermática
Neoplasias Testiculares/sangue
Neoplasias Testiculares/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadotropins); 0 (Hydroxyprogesterones); 3XMK78S47O (Testosterone); 409J2J96VR (Androstenedione)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180220
[Lr] Data última revisão:
180220
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180118
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0862


  5 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29334271
[Au] Autor:Corona G; Rastrelli G; Reisman Y; Sforza A; Maggi M
[Ad] Endereço:a Endocrinology Unit, Medical Department , Maggiore-Bellaria Hospital, Azienda-Usl Bologna , Bologna , Italy.
[Ti] Título:The safety of available treatments of male hypogonadism in organic and functional hypogonadism.
[So] Source:Expert Opin Drug Saf;17(3):277-292, 2018 Mar.
[Is] ISSN:1744-764X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:INTRODUCTION: In the case of primary male hypogonadism (HG), only testosterone (T) replacement therapy (TRT) is possible whereas when the problem is secondary to a pituitary or hypothalamus alteration both T production and fertility can be, theoretically, restored. We here systematically reviewed and discussed the advantages and limits of medications formally approved for the treatment of HG. Areas covered: Data derived from available meta-analyses of placebo controlled randomized trials (RCTs) were considered and analyzed. Gonadotropins are well-toleratedand their use is mainly limited by higher costs and a more cumbersome treatment schedule than TRT. Available RCTs on TRT suggest that cardiovascular (CV) and venous thromboembolism risk is not a major issue and that prostate safety is guaranteed. The risk of increased hematocrit is mainly limited to the use of short terminjectable preparations. Expert opinion: In the last few years the concept of 'organic' irreversible HG and 'functional' or age- and comorbidity-related HG has been introduced. This definition is not evidence-based. The majority of RCTs enrolled patients with 'functional' HG. Considering the significant improvement in body composition, glucose metabolism and sexual activity, TRT should not be limited to 'organic' HG, but also offered for 'functional'.
[Mh] Termos MeSH primário: Gonadotropinas/administração & dosagem
Hipogonadismo/tratamento farmacológico
Testosterona/administração & dosagem
[Mh] Termos MeSH secundário: Gonadotropinas/efeitos adversos
Terapia de Reposição Hormonal/efeitos adversos
Terapia de Reposição Hormonal/métodos
Seres Humanos
Hipogonadismo/etiologia
Doenças Hipotalâmicas/complicações
Infertilidade Masculina/tratamento farmacológico
Infertilidade Masculina/etiologia
Masculino
Doenças da Hipófise/complicações
Ensaios Clínicos Controlados Aleatórios como Assunto
Testosterona/efeitos adversos
Testosterona/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Gonadotropins); 3XMK78S47O (Testosterone)
[Em] Mês de entrada:1802
[Cu] Atualização por classe:180215
[Lr] Data última revisão:
180215
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:180116
[St] Status:MEDLINE
[do] DOI:10.1080/14740338.2018.1424831


  6 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:29182666
[Au] Autor:Hietamäki J; Hero M; Holopainen E; Känsäkoski J; Vaaralahti K; Iivonen AP; Miettinen PJ; Raivio T
[Ad] Endereço:Pediatric Research Center, Children's Hospital, University of Helsinki and Helsinki University Hospital, Helsinki, Finland.
[Ti] Título:GnRH receptor gene mutations in adolescents and young adults presenting with signs of partial gonadotropin deficiency.
[So] Source:PLoS One;12(11):e0188750, 2017.
[Is] ISSN:1932-6203
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Biallelic, partial loss-of-function mutations in GNRHR cause a wide spectrum of reproductive phenotypes from constitutional delay of growth and puberty to complete congenital hypogonadotropic hypogonadism. We studied the frequency of GNRHR, FGFR1, TAC3, and TACR3 mutations in nine adolescent and young adult females with clinical cues consistent with partial gonadotropin deficiency (stalled puberty, unexplained secondary amenorrhea), and describe phenotypic features and molecular genetic findings of monozygotic twin brothers with stalled puberty. Two girls out of nine (22%, 95%CI 6-55%) carried biallelic mutations in GNRHR. The girl with compound heterozygous c.317A>G p.(Gln106Arg) and c.924_926delCTT p.(Phe309del) GNRHR mutations displayed incomplete puberty and clinical signs of hypoestrogenism. The patient carrying a homozygous c.785G>A p.(Arg262Gln) mutation presented with signs of hypoestrogenism and unexplained secondary amenorrhea. None of the patients exhibited mutations in FGFR1, TAC3, or TACR3. The twin brothers, compound heterozygous for GNRHR mutations c.317A>G p.(Gln106Arg) and c.785G>A p.(Arg262Gln), presented with stalled puberty and were discordant for weight, and the heavier of them had lower testosterone levels. These results suggest that genetic testing of the GNRHR gene should be offered to adolescent females with low-normal gonadotropins and unexplained stalled puberty or menstrual dysfunction. In male patients with partial gonadotropin deficiency, excess adipose tissue may suppress hypothalamic-pituitary-gonadal axis.
[Mh] Termos MeSH primário: Gonadotropinas/deficiência
Mutação
Receptores LHRH/genética
[Mh] Termos MeSH secundário: Adolescente
Adulto
Feminino
Seres Humanos
Masculino
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Gonadotropins); 0 (Receptors, LHRH)
[Em] Mês de entrada:1712
[Cu] Atualização por classe:171226
[Lr] Data última revisão:
171226
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171129
[St] Status:MEDLINE
[do] DOI:10.1371/journal.pone.0188750


  7 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28882981
[Au] Autor:Bonomi M; Vezzoli V; Krausz C; Guizzardi F; Vezzani S; Simoni M; Bassi I; Duminuco P; Di Iorgi N; Giavoli C; Pizzocaro A; Russo G; Moro M; Fatti L; Ferlin A; Mazzanti L; Zatelli MC; Cannavò S; Isidori AM; Pincelli AI; Prodam F; Mancini A; Limone P; Tanda ML; Gaudino R; Salerno M; Francesca P; Maghnie M; Maggi M; Persani L; Italian Network on Central Hypogonadism
[Ad] Endereço:Department of Clinical Sciences and Community HealthUniversity of Milan, Milan, Italy m.bonomi@auxologico.it marco.bonomi@unimi.it.
[Ti] Título:Characteristics of a nationwide cohort of patients presenting with isolated hypogonadotropic hypogonadism (IHH).
[So] Source:Eur J Endocrinol;178(1):23-32, 2018 Jan.
[Is] ISSN:1479-683X
[Cp] País de publicação:England
[La] Idioma:eng
[Ab] Resumo:OBJECTIVE: Isolated hypogonadotropic hypogonadism (IHH) is a rare disorder with pubertal delay, normal (normoosmic-IHH, nIHH) or defective sense of smell (Kallmann syndrome, KS). Other reproductive and non-reproductive anomalies might be present although information on their frequency are scanty, particularly according to the age of presentation. DESIGN: Observational cohort study carried out between January 2008 and June 2016 within a national network of academic or general hospitals. METHODS: We performed a detailed phenotyping of 503 IHH patients with: (1) manifestations of hypogonadism with low sex steroid hormone and low/normal gonadotropins; (2) absence of expansive hypothalamic/pituitary lesions or multiple pituitary hormone defects. Cohort was divided on IHH onset (PPO, pre-pubertal onset or AO, adult onset) and olfactory function: PPO-nIHH ( = 275), KS ( = 184), AO-nIHH ( = 36) and AO-doIHH (AO-IHH with defective olfaction, = 8). RESULTS: 90% of patients were classified as PPO and 10% as AO. Typical midline and olfactory defects, bimanual synkinesis and familiarity for pubertal delay were also found among the AO-IHH. Mean age at diagnosis was significantly earlier and more frequently associated with congenital hypogonadism stigmata in patients with Kallmann's syndrome (KS). Synkinesis, renal and male genital tract anomalies were enriched in KS. Overweight/obesity are significantly associated with AO-IHH rather than PPO-IHH. CONCLUSIONS: Patients with KS are more prone to develop a severe and complex phenotype than nIHH. The presence of typical extra-gonadal defects and familiarity for PPO-IHH among the AO-IHH patients indicates a common predisposition with variable clinical expression. Overall, these findings improve the understanding of IHH and may have a positive impact on the management of patients and their families.
[Mh] Termos MeSH primário: Hipogonadismo/fisiopatologia
[Mh] Termos MeSH secundário: Adolescente
Adulto
Idade de Início
Estudos de Coortes
Feminino
Hormônios Esteroides Gonadais/sangue
Gonadotropinas/sangue
Gonadotropinas/deficiência
Seres Humanos
Hipogonadismo/diagnóstico por imagem
Hipogonadismo/epidemiologia
Itália/epidemiologia
Masculino
Obesidade/complicações
Obesidade/epidemiologia
Transtornos do Olfato/complicações
Transtornos do Olfato/epidemiologia
Sobrepeso/complicações
Sobrepeso/epidemiologia
Fenótipo
Hormônios Hipofisários/sangue
Hormônios Hipofisários/deficiência
Sincinesia/complicações
Sincinesia/epidemiologia
Adulto Jovem
[Pt] Tipo de publicação:JOURNAL ARTICLE; OBSERVATIONAL STUDY
[Nm] Nome de substância:
0 (Gonadal Steroid Hormones); 0 (Gonadotropins); 0 (Pituitary Hormones)
[Em] Mês de entrada:1711
[Cu] Atualização por classe:171129
[Lr] Data última revisão:
171129
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:170909
[St] Status:MEDLINE
[do] DOI:10.1530/EJE-17-0065


  8 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28965550
[Au] Autor:Haas J; Casper RF
[Ad] Endereço:Division of Reproductive Sciences, University of Toronto; Lunenfeld-Tanenbaum Research Institute, Mount Sinai Hospital; and TRIO Fertility, Toronto, Ontario, Canada.
[Ti] Título:In vitro fertilization treatments with the use of clomiphene citrate or letrozole.
[So] Source:Fertil Steril;108(4):568-571, 2017 Oct.
[Is] ISSN:1556-5653
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:There has been increasing interest in combining the oral agents clomiphene citrate (CC) and letrozole with gonadotropins in IVF: for poor responders to reduce the amount of gonadotropins used, and in normal responders to reduce the incidence of ovarian hyperstimulation (OHSS). In normal responders, mild stimulation with the use of CC and gonadotropins was found to decrease the number of oocytes retrieved and result in good pregnancy rates, but in most studies the cumulative pregnancy rate was lower compared with conventional ovarian stimulation when frozen embryo transfers were considered. Coadministration of letrozole and gonadotropins has mainly been used in patients with breast cancer to prevent the massive elevation of serum E concentrations with the use of standard controlled ovarian hyperstimulation. CC and letrozole have both been used with gonadotropins in poor responders and have been shown to reduce the amount of gonadotropin used without reducing the pregnancy rate. Letrozole use with gonadotropins in IVF cycles may increase endometrial receptivity by increasing integrin expression in the endometrium and by lowering estrogen concentrations to more physiologic levels.
[Mh] Termos MeSH primário: Clomifeno/administração & dosagem
Fármacos para a Fertilidade Feminina/administração & dosagem
Fertilização In Vitro/métodos
Infertilidade Feminina/terapia
Nitrilos/administração & dosagem
Triazóis/administração & dosagem
[Mh] Termos MeSH secundário: Clomifeno/efeitos adversos
Quimioterapia Combinada/métodos
Feminino
Fármacos para a Fertilidade Feminina/efeitos adversos
Fertilização In Vitro/efeitos adversos
Gonadotropinas/administração & dosagem
Seres Humanos
Nitrilos/efeitos adversos
Síndrome de Hiperestimulação Ovariana/etiologia
Síndrome de Hiperestimulação Ovariana/prevenção & controle
Indução da Ovulação/métodos
Gravidez
Triazóis/efeitos adversos
[Pt] Tipo de publicação:JOURNAL ARTICLE; REVIEW
[Nm] Nome de substância:
0 (Fertility Agents, Female); 0 (Gonadotropins); 0 (Nitriles); 0 (Triazoles); 1HRS458QU2 (Clomiphene); 7LKK855W8I (letrozole)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171013
[Lr] Data última revisão:
171013
[Sb] Subgrupo de revista:IM
[Da] Data de entrada para processamento:171003
[St] Status:MEDLINE


  9 / 7838 MEDLINE  
              first record previous record next record last record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28938399
[Au] Autor:Chowdhury I; Branch A; Mehrabi S; Ford BD; Thompson WE
[Ad] Endereço:Department of Obstetrics and Gynecology, Morehouse School of Medicine, Atlanta, Georgia 30310.
[Ti] Título:Gonadotropin-Dependent Neuregulin-1 Signaling Regulates Female Rat Ovarian Granulosa Cell Survival.
[So] Source:Endocrinology;158(10):3647-3660, 2017 Oct 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Mammalian ovarian follicular development and maturation of an oocyte competent to be fertilized and develop into an embryo depends on tightly regulated, spatiotemporally orchestrated crosstalk among cell death, survival, and differentiation signals through extra- and intraovarian signals, as well as on a permissive ovarian follicular microenvironment. Neuregulin-1 (NRG1) is a member of the epidermal growth factor-like factor family that mediates its effects by binding to a member of the erythroblastoma (ErbB) family. Our experimental results suggest gonadotropins promote differential expression of NRG1 and erbB receptors in granulosa cells (GCs), and NRG1 in theca cells during follicular development, and promote NRG1 secretions in the follicular fluid (FF) of rat ovaries. During the estrous cycle of rat, NRG1 and erbB receptors are differentially expressed in GCs and correlate positively with serum gonadotropins and steroid hormones. Moreover, in vitro experimental studies suggest that the protein kinase C inhibitor staurosporine (STS) causes the physical destruction of GCs by the activation of caspase-3. Exogenous NRG1 treatment of GCs delayed onset of STS-induced apoptosis and inhibited cleaved caspase-3 expressions. Moreover, exogenous NRG1 treatment of GCs alters STS-induced death by maintaining the expression of ErbB2, ErbB3, pAkt, Bcl2, and BclxL proteins. Taken together, these studies demonstrate that NRG1 is gonadotropin dependent, differentially regulated in GCs and theca cells, and secreted in ovarian FF as an intracellular survival factor that may govern follicular maturation.
[Mh] Termos MeSH primário: Apoptose/efeitos dos fármacos
Sobrevivência Celular
Receptores ErbB/efeitos dos fármacos
Gonadotropinas/farmacologia
Células da Granulosa/efeitos dos fármacos
Neuregulina-1/efeitos dos fármacos
[Mh] Termos MeSH secundário: Animais
Caspase 3/efeitos dos fármacos
Caspase 3/metabolismo
Receptores ErbB/metabolismo
Feminino
Líquido Folicular
Células da Granulosa/metabolismo
Técnicas In Vitro
Neuregulina-1/metabolismo
Neuregulina-1/farmacologia
Folículo Ovariano/crescimento & desenvolvimento
Ovário/citologia
Ovário/efeitos dos fármacos
Ovário/metabolismo
Fosfoproteínas/efeitos dos fármacos
Fosfoproteínas/metabolismo
Proteína Quinase C/antagonistas & inibidores
Proteínas Proto-Oncogênicas c-akt/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-akt/metabolismo
Proteínas Proto-Oncogênicas c-bcl-2/efeitos dos fármacos
Proteínas Proto-Oncogênicas c-bcl-2/metabolismo
Ratos
Ratos Sprague-Dawley
Receptor ErbB-2/efeitos dos fármacos
Receptor ErbB-2/metabolismo
Receptor ErbB-3/efeitos dos fármacos
Receptor ErbB-3/metabolismo
Estaurosporina/farmacologia
Células Tecais
Proteína bcl-X/efeitos dos fármacos
Proteína bcl-X/metabolismo
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Bcl2 protein, rat); 0 (Bcl2l1 protein, rat); 0 (Gonadotropins); 0 (Neuregulin-1); 0 (Nrg1 protein, rat); 0 (Phosphoproteins); 0 (Proto-Oncogene Proteins c-bcl-2); 0 (bcl-X Protein); EC 2.7.10.1 (ErbB Receptors); EC 2.7.10.1 (Erbb2 protein, rat); EC 2.7.10.1 (Erbb3 protein, rat); EC 2.7.10.1 (Receptor, ErbB-2); EC 2.7.10.1 (Receptor, ErbB-3); EC 2.7.11.1 (Proto-Oncogene Proteins c-akt); EC 2.7.11.13 (Protein Kinase C); EC 3.4.22.- (Casp3 protein, rat); EC 3.4.22.- (Caspase 3); H88EPA0A3N (Staurosporine)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170923
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00065


  10 / 7838 MEDLINE  
              first record previous record
seleciona
para imprimir
Fotocópia
Texto completo
[PMID]:28911172
[Au] Autor:Kreisman MJ; Song CI; Yip K; Natale BV; Natale DR; Breen KM
[Ad] Endereço:Department of Reproductive Medicine, University of California, San Diego, La Jolla, California 92093-0674.
[Ti] Título:Androgens Mediate Sex-Dependent Gonadotropin Expression During Late Prenatal Development in the Mouse.
[So] Source:Endocrinology;158(9):2884-2894, 2017 Sep 01.
[Is] ISSN:1945-7170
[Cp] País de publicação:United States
[La] Idioma:eng
[Ab] Resumo:Central organization of the hypothalamic-pituitary-gonadal axis is initiated during fetal life. At this critical time, gonadal hormones mediate sex-specific development of the hypothalamic-pituitary axis, which then dictates reproductive physiology and behavior in adulthood. Although studies have investigated the effects of prenatal androgens on central factors influencing gonadotropin-releasing hormone (GnRH) release, the impact of fetal androgens on gonadotrope function has been overlooked. In the current study, we demonstrated that gonadotropin gene expression and protein production were robustly elevated in female mice compared with males during late fetal development and that this sex difference was dependent on fetal androgens. Treatment of dams from embryonic day (E)15.5 to E17.5 with testosterone, dihydrotestosterone (DHT), or the androgen antagonist flutamide eliminated the sex difference at E18.5. Specifically, flutamide relieved the suppression in male gene expression, elevating the level to that of females, whereas testosterone or DHT attenuated female gene expression to male levels. The gonadotrope population is equivalent in males and females, and gonadotropic cells in both sexes express androgen receptors, suggesting that androgen-dependent transcriptional regulation can occur in these cells in either sex. Studies using mouse models lacking GnRH signaling show that GnRH is necessary for enhanced gonadotropin expression in females and is therefore required to observe the sex difference. Collectively, these data suggest that circuits controlling GnRH input to the fetal pituitary are unrestrained in females yet robustly inhibited in males via circulating androgens and demonstrate plasticity in gonadotropin synthesis and secretion in both sexes depending on the androgen milieu during late prenatal development.
[Mh] Termos MeSH primário: Androgênios/farmacologia
Desenvolvimento Fetal
Gonadotropinas/genética
[Mh] Termos MeSH secundário: Animais
Contagem de Células
Embrião de Mamíferos
Feminino
Desenvolvimento Fetal/efeitos dos fármacos
Desenvolvimento Fetal/genética
Expressão Gênica/efeitos dos fármacos
Idade Gestacional
Gonadotrofos/citologia
Gonadotropinas/metabolismo
Masculino
Camundongos
Camundongos Endogâmicos C57BL
Camundongos Knockout
Hipófise/citologia
Hipófise/embriologia
Gravidez
Caracteres Sexuais
[Pt] Tipo de publicação:JOURNAL ARTICLE
[Nm] Nome de substância:
0 (Androgens); 0 (Gonadotropins)
[Em] Mês de entrada:1710
[Cu] Atualização por classe:171115
[Lr] Data última revisão:
171115
[Sb] Subgrupo de revista:AIM; IM
[Da] Data de entrada para processamento:170916
[St] Status:MEDLINE
[do] DOI:10.1210/en.2017-00285



página 1 de 784 ir para página                         
   


Refinar a pesquisa
  Base de dados : MEDLINE Formulário avançado   

    Pesquisar no campo  
1  
2
3
 
           



Search engine: iAH v2.6 powered by WWWISIS

BIREME/OPAS/OMS - Centro Latino-Americano e do Caribe de Informação em Ciências da Saúde